eMultipleSclerosis Review

In the clinical trials of new MS medications and procedures, why has the participation of racial and ethnic minority individuals been so low? Is it a difficulty with outreach? Are the patient barriers to participation underrecognized and underaddressed? Does historical mistrust of the medical community remain a strong negative? What should clinicians and trial designers do to increase diversity to improve care for all individuals with MS?Take our post-test to claim CME credits (https://elit.dkbmed.com/issues/223/test)Read this podcast's companion newsletter here. (https://elit.dkbmed.com/issues/221) Hosted on Acast. See acast.com/privacy for more information.

The long-anticipated advances in therapeutic treatments to improve outcomes in both relapsing and progressive MS are coming closer to fruition. Although much of the evidence is still preclinical, the variety and scope of the ongoing research promises to provide new and novel options to manage this disease in the relatively near future.Take our post-test to claim CME credits (https://elit.dkbmed.com/issues/222/test)Read this podcast's companion newsletter here. (https://elit.dkbmed.com/issues/218) Hosted on Acast. See acast.com/privacy for more information.

The long-anticipated advances in therapeutic treatments to improve outcomes in both relapsing and progressive MS are coming closer to fruition. Although much of the evidence is still preclinical, the variety and scope of the ongoing research promises to provide new and novel options to manage this disease in the relatively near future.Take our post-test to claim CME credits (https://elit.dkbmed.com/issues/219/test)Read this podcast's companion newsletter here. (https://elit.dkbmed.com/issues/216) Hosted on Acast. See acast.com/privacy for more information.

Giving birth and raising a family. For many people with MS, the path to achieving those goals contains more questions than answers. Questions about timing — which should come first, pregnancy or disease stability on a DMT? Questions about genetics — can MS be passed on to the baby? Questions about fertility — is in vitro fertilization safe and effective, and how much does it increase disease activity? Questions their treating clinicians may not be able to answer with the most current research.Take our post-test to claim CME credits (https://elit.dkbmed.com/issues/215/test)Read this podcast's companion newsletter here. (https://elit.dkbmed.com/issues/214) Hosted on Acast. See acast.com/privacy for more information.

In this issue: Fatigue. It’s one of the most common complaints providers hear from their patients with MS. It interferes with virtually every aspect of a patient’s life. What can clinicians do to better identify MS fatigue? And what do they need to know to better provide management effectively tailored to each patient?Take our post-test to claim CME credits (https://elit.dkbmed.com/issues/211/test)Read this podcast's companion newsletter here. (https://elit.dkbmed.com/issues/210) Hosted on Acast. See acast.com/privacy for more information.

In this issue: POMS. Pediatric Onset Multiple Sclerosis: children and adolescents with symptoms indicating a diagnosis of multiple sclerosis. Are their presentations different from adult-onset MS? POMS is often associated with higher degrees of activity and inflammation early in the disease. How can clinicians most effectively confirm an early MS diagnosis in these young patients? What does the current evidence show about when to prescribe high-efficacy disease modifying therapies? What activity limitations should be placed on patients with POMS?Take our post-test to claim CME credits (https://elit.dkbmed.com/issues/209/test)Read this podcast's companion newsletter here. (https://elit.dkbmed.com/issues/208) Hosted on Acast. See acast.com/privacy for more information.

Hosted on Acast. See acast.com/privacy for more information.

Has the place for BTK inhibitors in MS been determined? How well do extended interval or alternative B cell depletion dosing regimens work, and for which patients? Do the data support HSCT (hematopoietic stem cell transplant) over high-efficacy DMT — again, for which patients, and with what efficacy and safety?Join us, as guest host Dr. Cole Harrington from the Ohio State University explores these important topics in this issue of eMultipleSclerosis Review.Take our post-test to claim CME credits (https://elit.dkbmed.com/issues/178/test)Read this podcast's companion newsletter here. (https://elit.dkbmed.com/issues/176) Hosted on Acast. See acast.com/privacy for more information.

What’s the evidence supporting the existence of an MS prodromal phase — where the biology of the disease has begun but the symptoms typical of MS have not yet appeared? Are there biomarkers to help identify it? Imaging abnormalities? And how can diagnosing a prodrome benefit patients?Join us as we discuss these questions with Dr. Naila Makhani from Yale School of Medicine, in this video podcast issue of eMultipleSclerosis Review.Take our post-test to claim CME credits.Read this podcast's companion newsletter here. Hosted on Acast. See acast.com/privacy for more information.

Clinicians prescribing the increasingly higher efficacy B-cell depletion or S1P modulators therapies — how aware are they of the newer concerns about safety? Which of their patients may be in greater danger of acquiring PML and/or opportunistic infections? The vaccinations commonly recommended for the general population (eg, COVID-19) — do individuals with MS respond differently, and what should clinicians do about it? What do the data say?Join us, as Dr. Le Hua and Dr. Areeba Siddiqui from the Cleveland Clinic’s Lou Ruvo Center for Brain Health explore these questions in this issue of eMultipleSclerosis Review.Take our post-test to claim CME credits.Read this podcast's companion newsletter here. Hosted on Acast. See acast.com/privacy for more information.